Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024
Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...
Seeking Alpha14d
Neurocrine Biosciences, Inc. (NBIX) Q4 2024 Earnings Call Transcript
Neurocrine's Phase 3 pipeline is also set to ... study give us the confidence and conviction to rapidly advance this molecule into Phase 3 studies as well as to initiate a Phase 2 study in bipolar ...
Times Union14d
Neurocrine: Q4 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — Neurocrine Biosciences Inc. (NBIX) on Thursday reported fourth-quarter earnings of $103.1 million. The San Diego-based company said it had profit of $1 per share.
Morningstar14d
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025
Intercontinental Exchange and RELX are among the stocks that are now expensive. We sell different types of products and services to both investment professionals and individual investors. These ...
Yahoo Finance14d
Neurocrine: Q4 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — Neurocrine Biosciences Inc. (NBIX) on Thursday reported fourth-quarter earnings of $103.1 million. The San Diego-based company said it had profit of $1 per share. The ...